Industry News

• Optogenetics project takes top NIDA Addiction Science Award  A project that maps dopamine circuits in the prefrontal cortex through optogenetic manipulation was given top honors in this year's annual Addiction Science Awards at the 2012 Intel International Science and Engineering Fair — the world's largest science competition for high school students.
  May 18, 2012  
• TGen’s Melissa Ray named to board of directors of Arizona Technology Council  Melissa Ray, Director of the Office of Project Management at the TGen, has been appointed to the Board of Directors of the Arizona Technology Council. The Arizona Technology Council Board represents the interests of Arizona's technology industries.
  May 18, 2012  
• Phase 3 data show NUCYNTA ER (tapentadol) extended-release tablets provide pain management  Janssen announced results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.
  May 18, 2012  
• ArQule and Daiichi Sankyo announce completion of patient recruitment in phase 3 trial  ArQule and Daiichi Sankyo announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib.
  May 18, 2012  
• Monsanto announces $50 million commitment to African agricultural development  Monsanto announced the company's support of the New Vision for Agriculture Initiative, the Grow Africa Partnership and the G8's New Alliance for Food Security and Nutrition through a $50 million commitment over the next ten years to support sustained Africa agricultural development and growth.
  May 18, 2012  
• Pfizer exploratory study measures effects of Lyrica (pregabalin) on brain activity  Pfizer announced results of studies on Lyrica® (pregabalin) capsules CV that included exploratory research designed to provide new insight into how Lyrica works in the brains of patients with fibromyalgia. Previously reported results showed that Lyrica reduced glutamate in fibromyalgia patients.
  May 18, 2012  
• OraSure Technologies announces rapid HCV testing initiatives for National Hepatitis Day  OraSure announced its support of numerous rapid hepatitis C (HCV) testing initiatives for the first National Hepatitis Testing Day on May 19. These testing initiatives will help encourage thousands of people across the U.S. to get tested for hepatitis C with the OraQuick® Rapid HCV test.
  May 18, 2012  
• NIH study finds that coffee drinkers have lower risk of death  caffeinated or decaffeinated — had a lower risk of death overall than others who did not drink coffee, according a study by researchers from the NCI and AARP. The results of the study were published in the New England Journal of Medicine.
  May 17, 2012  
• World's first approved stem cell drug receives clearance from Health Canada  Osiris announced it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. The decision marks the world's first regulatory approval of a manufactured stem cell product.
  May 17, 2012  
• Neurocrine Biosciences announces Urocortin 2 phase II study results   Neurocrine announced efficacy and safety results from a Phase II trial of urocortin 2 in patients with acute decompensated heart failure. The study was conducted over a two year period. Infusion of urocortin 2 was generally well tolerated and there were no treatment-related serious adverse events.
  May 17, 2012  

   (next 10 articles)